Molecular Oncology
Volume 3, Issue 5 , Pages 394-401 , December 2009

Review on early technology assessments of nanotechnologies in oncology

  • Valesca P. Retèl

      Affiliations

    • Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
    • ,
  • Marjan J.M. Hummel

      Affiliations

    • School of Governance and Management, University of Twente, MB-HTSR, P.O. Box 217, 7500 AE Enschede, The Netherlands
    • ,
  • Wim H. van Harten

      Affiliations

    • Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
    • School of Governance and Management, University of Twente, MB-HTSR, P.O. Box 217, 7500 AE Enschede, The Netherlands
    • Corresponding Author InformationCorresponding author at: Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel.: +31 20 5122860; fax: +31 20 6691449.

Received 2 February 2009 ,Revised 11 May 2009 ,Accepted 11 May 2009.

References 

  1. Baumgartner W, Jackli B, Schmithusen B, Weber F, Borrer C, Bucher C, et al. Nanotechnology in Medicine. Bern: TA-SWISS, Centre for Technology Assessment; 2003;25–35. Ref Type: Report
  2. Capri S, Cattaneo G. Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy. Clin. Ther. 2003;25(6):1826–1845
  3. Cox A, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 2007;39(3):352–358
  4. Douma KF, Karsenberg K, Hummel MJ, Bueno-de-Mesquita JM, van Harten WH. Methodology of constructive technology assessment in health care. Int. J. Technol. Assess. Health Care. 2007;23(2):162–168
  5. Dranitsaris G, Cottrell W, Spirovski B, Hopkins S. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J. Oncol. Pharm. Pract. 2008;
  6. Easton DF, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087–1093
  7. Faunce T, Shats K. Researching safety and cost-effectiveness in the life cycle of nanomedicine. J. Law Med. 2007;15(1):128–135
  8. Faunce TA. Nanotherapeutics: new challenges for safety and cost-effectiveness regulation in Australia. Med. J. Aust. 2007;186(4):189–191
  9. Forbes C, Wilby J, Richardson G, Sculpher M, Mather L, Riemsma R. A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer. Health Technol. Assess. 2002;6(23):1–119
  10. Fountzilas G, et al. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 2006;17(10):1560–1567
  11. Goh AS, et al. A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device–a first-in-man study. Int. J. Radiat. Oncol. Biol. Phys. 2007;67(3):786–792
  12. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006;17(8):1263–1268
  13. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ. Health Perspect. 2006;114(2):165–172
  14. Hede S, Huilgol N. “Nano”: the new nemesis of cancer. J. Cancer Res. Ther. 2006;2(4):186–195
  15. Hjortsberg C, Persson U, Lidbrink E, Bennett C. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta Oncol. 1999;38(8):1063–1067
  16. Hopper C, Niziol C, Sidhu M. The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral. Oncol. 2004;40(4):372–382
  17. Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 2002;95(10):2160–2168
  18. Hutton J, Trueman P, Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. Int. J. Technol. Assess. Health Care. 2007;23(4):425–432
  19. Institute of Medicine (IOM) . Crossing the Quality Chasm: a New Health System for the 21st Century. National Academy Press; 2001;
  20. Ioannidis JP. Is molecular profiling ready for use in clinical decision making?. Oncologist. 2007;12(3):301–311
  21. Jain KK. Innovations, challenges and future prospects of oncoproteomics. Mol. Oncol. 2008;153–160no. 2
  22. Jain KK. Nanomedicine: application of nanobiotechnology in medical practice. Med. Princ. Pract. 2008;17(2):89–101
  23. Jain KK. Recent advances in nanooncology. Technol. Cancer Res. Treat. 2008;7(1):1–13
  24. Jain KK. The Handbook of Nanomedicine. Totowa, USA: Springer/ Humana Press; 2008;
  25. Jain KK. Role of nanobiotechnology in developing personalized medicine for cancer. Technol. Cancer Res. Treat. 2005;4(6):645–650
  26. Jain KK. Applications of nanobiotechnology in clinical diagnostics. Clin. Chem. 2007;53(11):2002–2009
  27. Jain KK. Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev. Mol. Diagn. 2003;3(2):153–161
  28. Kim S, et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol. 2004;22(1):93–97
  29. Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol. Assess. 2006;10(9):1–132
  30. Maynard AD, et al. Safe handling of nanotechnology. Nature. 2006;444(7117):267–269
  31. Miller MR, Dunham JP, Amores A, Cresko WA, Johnson EA. Rapid and cost-effective polymorphism identification and genotyping using restriction site associated DNA (RAD) markers. Genomic. Res. 2008;17:240–248
  32. Mowatt G, Bower DJ, Brebner JA, Cairns JA, Grant AM, McKee L. When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies. Health Technol. Assess. 1997;1(14):i–149
  33. National Cancer Institute . Nanotechnology in Cancer: Tools to Relieve Human Suffering. Available at: 2008;http://nano.cancer.gov/resource_center/tech_backgrounder.aspRef Type: Generic
  34. National Cancer Institute . A Snapshot of Nanotechnology. 2008;Available at: http://planning.cancer.gov/disease/Nanotechnology-Snapshot.pdfRef Type: Report
  35. Oestreicher N, Ramsey SD, Linden HM, McCune JS, Van't Veer LJ, Burke W, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?. Genet Med. 2005;7(6):380–389
  36. Ojeda B, de Sande LM, Casado A, Merino P, Casado MA. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br. J. Cancer. 2003;89(6):1002–1007
  37. Pietzsch JB, Pate-Cornell ME. Early technology assessment of new medical devices. Int. J. Technol. Assess. Health Care. 2008;24(1):36–44
  38. Porter CA, Rifkin RM. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma. Clin. Lymphoma Myeloma. 2007;7(Suppl. 4):S150–S155
  39. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal. Bioanal. Chem. 2006;384(3):620–630
  40. Poulsen PB. Health Technology Assessment and Diffusion of Health Technology: 2000. Denmark: Odense University Press; 2000;
  41. Retel VP, et al. Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics. Int. J. Technol. Assess. Health Care. 2009;25(1):73–83
  42. Retel VP, Hummel MJ, van Harten WH. Early phase technology assessment of nanotechnology in oncology. Tumori. 2008;94:284–290
  43. Schot J, Rip A. The past and future of constructive technology assessment. Technol. Forecast. Soc. Change. 1996;54:251–268
  44. Schot JW. Constructive technology assessment and technology dynamics: the case of clean technologies. Sci. Technol. Hum. Values. 1992;17(1):36–56
  45. Silberglitt R, Anton P, Howell D, Wong A. The Global Technology Revolution 2020. 1–28 Pittsburgh: RAND Corporation; 2006;Ref Type: Report
  46. Singh S, Nalwa HS. Nanotechnology and health safety–toxicity and risk assessments of nanostructured materials on human health. J. Nanosci. Nanotechnol. 2007;7(9):3048–3070
  47. Smith DH, Adams JR, Johnston SR, Gordon A, Drummond MF, Bennett CL. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann. Oncol. 2002;13(10):1590–1597
  48. The Medical Advisory Secretariat . OMoHaL-TC. Nanotechnology, Horizon Scanning Appraisal. 1–40 The Medical Advisory Secretariat; 2006;Ref Type: Report
  49. US Food and Drug Administration Nanotechnology Taskforce . Nanotechnology, a Report of the U.S. Food and Drug Administration Nanotechnology Task Force. Public Health Service; 2007;Ref Type: Report
  50. Vanni T, Fonseca BA, Polanczyk CA. Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil. HIV Clin. Trials. 2006;7(4):194–202
  51. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin. 2008;58(2):97–110
  52. Wilson RF. Nanotechnology: the challenge of regulating known unknowns. J. Law Med. Ethics. 2006;34(4):704–713
  53. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat. Biotechnol. 2003;21(1):41–46
  54. Yang T-H, Chen C-T, Wang C-P, Lou P-J. Photodynamic therapy suppresses the migration and invasion of head and neck cancer cells in vitro. Oral. Oncol. 2007;43:358–365

PII: S1574-7891(09)00072-6

doi: 10.1016/j.molonc.2009.05.001

Molecular Oncology
Volume 3, Issue 5 , Pages 394-401 , December 2009

Article Tools

* Image Usage & Resolution